预约演示
Nuvectis receives orphan drug designation for cholangiocarcinoma therapy
2023-08-18
孤儿药快速通道临床1期
Cholangiocarcinoma accounts for approximately 3% of all gastrointestinal malignancies. Credit: Explode / Shutterstock.com.
Cholangiocarcinomas received orphan drug designation frogastrointestinal malignanciesstration (FDA) for NXP800 to treat cholangiocarcinoma.
Nuvectis Pharma molecule taken orally, is currently being assesseFood and Drug Administration (FDA)NXP800cholangiocarcinoma
NXP800ended Reports
ReportsLOA and PTSR Model - Camrelizumab in Malignant Pleural Mesothelioma GlobalData
ReportsLOA and PTSR Model - Anetumab Corixetan in Malignant Mesothelioma GlobalData
View allCompanies IntelligenCamrelizumabharmMalignant Pleural Mesothelioma
The study is designed to explore the drug candidate’s clinical activity as a potential treatment for platinum-resistant, ARID1a-mutated ovarian carcinoma.
Nuvectis has already receiveAnetumabrCorixetannatiMalignant Mesotheliomalopment programme.
It is also developing another drug candidate, NXP900, a new small molecule inhibitor targeting the SRC/YES1 kinases.
The FDA has cleared the IND for NXP900 and a Phase Ia dose escalation trial is yet to commence.ARID1a
“This orphan drug designation is an important NXP900one in our journey toward our mission of developing NXP800 for the treatment of serious conditions of unmet medical need in oncology.”
Nuvectisannual incidence of nearly 8,000 to 10,NXP800 the US, it accounts for around 3% of all gastrointestinal malignancies.cancerARID1a-mutated ovarian, endometrial and gastric carcinomasARID1acholangiocarcinoma
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。